Description
A-108 MONITORING ISSUES OF DIRECT ANTI-XA ORAL ANTICOAGULANTS AND LOW MOLECULAR WEIGHT HEPARINS, DURING BRIDGING WITH LMWH THERAPY
Article: A-108 MONITORING ISSUES OF DIRECT ANTI-XA ORAL ANTICOAGULANTS AND LOW MOLECULAR WEIGHT HEPARINS, DURING BRIDGING WITH LMWH THERAPY
€3.03
Related products
-
Article: INTRODUCTION
€3.03 Add to cart -
Article: Highlights in melanoma
€3.03 Add to cart -
Article: Calendar of events
€3.03 Add to cart -
Article: Clinically meaningful survival benefit with atezolizumab + nab-paclitaxel in previously untreated patients with PD-L1+ metastatic triple negative breast cancer
€3.03 Add to cart
Reviews
There are no reviews yet.